To better understand the relationship between bioactive LMs and different aspects of CNS related pathophysiologic processes in MS, in this study, we investigated bioactive LM levels belonging to the ω-3/ω-6 lipid classes in plasma of different MS phenotypes, and we determined whether and how these levels relate to disability outcome measures, brain volumes, and the blood biomarkers serum NfL (sNfL) and serum GFAP (sGFAP). The gene discussed is GFAP; the disease is myeloid sarcoma.